CG Oncology (CGON) Income towards Parent Company (2023 - 2025)
Historic Income towards Parent Company for CG Oncology (CGON) over the last 3 years, with Q3 2025 value amounting to -$43.7 million.
- CG Oncology's Income towards Parent Company fell 11422.34% to -$43.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$151.4 million, marking a year-over-year decrease of 10798.61%. This contributed to the annual value of -$88.0 million for FY2024, which is 8136.16% down from last year.
- As of Q3 2025, CG Oncology's Income towards Parent Company stood at -$43.7 million, which was down 11422.34% from -$41.4 million recorded in Q2 2025.
- CG Oncology's Income towards Parent Company's 5-year high stood at -$8.7 million during Q1 2023, with a 5-year trough of -$43.7 million in Q3 2025.
- In the last 3 years, CG Oncology's Income towards Parent Company had a median value of -$18.9 million in 2024 and averaged -$23.3 million.
- Per our database at Business Quant, CG Oncology's Income towards Parent Company crashed by 6365.21% in 2024 and then tumbled by 11904.81% in 2025.
- Over the past 3 years, CG Oncology's Income towards Parent Company (Quarter) stood at -$16.6 million in 2023, then crashed by 92.16% to -$31.8 million in 2024, then crashed by 37.43% to -$43.7 million in 2025.
- Its Income towards Parent Company stands at -$43.7 million for Q3 2025, versus -$41.4 million for Q2 2025 and -$34.5 million for Q1 2025.